Skip to main content
TipRanks
Go Ultimate75% OFF

Oncopeptides AB (ONCO) AI Stock Analysis

11 Followers
SE:ONCO

Oncopeptides AB

(Nasdaq OMX AB:ONCO)

Select Model
Rating:47Neutral
Price Target:SEK 1.50▼(-8.54% Downside)
Action:reiterated
Date:11/13/26

The overall score is heavily pressured by the company's precarious financial position, marked by insolvency and significant cash burn, which represents an existential risk. This is partially offset by a very positive earnings call, which highlighted strong commercial momentum for Pepaxti, a near-term catalyst in a label expansion, and a promising new pipeline opportunity in glioblastoma. Technical and valuation metrics remain weak, reflecting the company's current unprofitable state.

Positive Factors
Strong Pepaxti sales growthRapid sales growth and more than SEK 100 million in trailing-12-month revenue show increasing commercial adoption of Pepaxti. Continued expansion across European markets can improve operating leverage and establish a durable revenue base as the prescriber footprint develops.
Negative Factors
Persistent operating and net lossesDespite improving revenue and gross margin, the company remains deeply unprofitable because operating costs substantially exceed gross profit. Persistent losses reduce internal funding capacity and mean that commercial growth must accelerate considerably before the business can achieve sustainable earnings.

Oncopeptides AB (ONCO) vs. iShares MSCI Sweden ETF (EWD)

-80%-60%-40%-20%0%20%40%SE:ONCO-67.51%EWD+8.63%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 707.43M
Dividend Yield
―
Average Volume (3M)
5.42M
Price to Earnings (P/E)
-2.6
Beta (1Y)
0.12
Revenue Growth
65.37%
EPS Growth
43.28%
Country
Sweden
Employees
71
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

Oncopeptides AB Business Overview & Revenue Model

Company Description

Oncopeptides AB (publ) is a biotechnology firm dedicated to developing medical therapies for cancer, serving markets across the United States, Europe, and worldwide. Its foremost experimental compound, melflufen, is a distinct peptide-drug conjugate...

Oncopeptides AB Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:-4.87%|Next Earnings Date:Feb 18, 2027
Earnings Call SentimentPositive

The call was strongly constructive, with accelerating Pepaxti sales, approximately 98% gross margins, lower operating expenses, improved operating leverage, strengthened financing, a positive CHMP opinion for third-line expansion, and positive initial human glioblastoma data. The main negatives were Q3 seasonality, a flat German market, the still-pending European Commission decision, uncertainty around the glioblastoma development path, additional clinical program costs, and the delayed Japanese partnership process. Highlights significantly outweighed the lowlights.

Positive Updates

Strong Q3 and Nine-Month Sales Growth
Q3 net sales reached SEK 28.5 million, up 41% year over year from SEK 20.2 million. First-nine-month sales reached SEK 84.9 million, up 61% to 62% year over year from SEK 52.6 million, and trailing-12-month sales exceeded SEK 100 million for the first time, reaching SEK 103.5 million.

Negative Updates

Seasonal Impact on Q3 Demand
The European summer vacation period caused demand to be softer during August and September, with the most pronounced seasonal impact in Germany. Management described Q3 as a weaker quarter than Q2 on a quarter-over-quarter basis, although it still delivered 41% year-over-year growth.

Company Guidance

Management remains on track to achieve positive cash flow during 2027, with the cash flow guidance based on European Pepaxti commercial operations becoming self-sustaining; the target was expressed before the third-line opportunity, although third line “will help reach our target ... for sure.” Total operating cost “just below SEK 300 million” is expected to remain a relevant benchmark for the full year 2026, while the commercial part of Oncopeptides is expected to run “more or less on the same cost base” in 2027, excluding additional glioblastoma costs. For Q4, management is not commenting on the current quarter but expects, “granted that nothing really unexpected happens,” the trend to be “more similar to the year before,” with Q4 “commonly stronger than Q3” and “more into the 2024 trend rather than the 2025 trend.” The formal European Commission decision is expected “in the coming weeks,” “no later than 60 days following a CHMP decision,” followed by a German reimbursement dossier “within approximately one month” of a positive decision; glioblastoma development could reach market “rather sooner than later,” with a program “much shorter” than average time to market, including “accelerated approval in the U.S.,” “potential faster approval” in Europe, and “most likely orphan drug designation.”

Oncopeptides AB Financial Statement Overview

Summary

Financial health is critically weak. The income statement shows strong revenue growth and excellent gross margins, but the company is deeply unprofitable. The balance sheet is under severe stress with negative equity, indicating insolvency risk. Cash flow is a major concern, with operating losses translating directly into cash burn, making the company dependent on external financing.

Income Statement

35Negative

Balance Sheet

10Very Negative

Cash Flow

30Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue103.50M71.12M31.65M35.22M8.36M118.30M
Gross Profit99.90M59.00M28.98M36.30M8.35M65.17M
EBITDA-180.27M-219.26M-261.81M-231.62M-319.64M-1.41B
Net Income-196.04M-249.59M-284.61M-249.11M-337.95M-1.43B
Balance Sheet
Total Assets175.87M134.84M244.19M238.38M385.32M439.38M
Cash, Cash Equivalents and Short-Term Investments116.84M82.25M178.54M173.44M344.51M364.30M
Total Debt140.42M139.39M141.72M126.16M9.54M14.19M
Total Liabilities192.37M193.73M189.91M181.60M91.03M228.51M
Stockholders Equity-16.50M-58.89M54.28M56.78M294.29M210.87M
Cash Flow
Free Cash Flow-192.57M-222.88M-260.57M-279.61M-423.02M-1.52B
Operating Cash Flow-192.57M-222.88M-260.57M-279.49M-420.51M-1.52B
Investing Cash Flow00496.00K-116.00K-2.51M-339.00K
Financing Cash Flow162.95M128.55M263.81M106.89M392.40M1.03B

Oncopeptides AB Technical Analysis

Technical Analysis SentimentNegative
Last Price1.64

Price Trends

50DMA1.91Negative
100DMA1.79Negative
200DMA1.72Negative

Market Momentum

MACD-0.05Negative
RSI40.12Neutral
STOCH7.28Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ONCO, the sentiment is Negative. The current price of 1.64 is below the 20-day moving average (MA) of 1.71, below the 50-day MA of 1.91, and below the 200-day MA of 1.72, indicating a bearish trend. The MACD of -0.05 indicates Negative momentum. The RSI at 40.12 is Neutral, neither overbought nor oversold. The STOCH value of 7.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:ONCO.

Oncopeptides AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:ONCO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CANTASE:CANTA83OutperformSEK 360.89M1.9063.09%―――
SE:SPRINTSE:SPRINT80OutperformSEK 400.96M5.4971.44%―170.38%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:IMMUSE:IMMU48NeutralSEK 217.58M-1.96-19.14%――13.06%
SE:ONCOSE:ONCO47NeutralSEK 729.43M-2.60――65.37%43.28%
SE:ATORXSE:ATORX39UnderperformSEK 30.33M-0.01-439.98%―-99.33%64.90%
SE:BINVSE:BINV37UnderperformSEK 142.80M-0.28-128.54%―-83.67%-50.29%

* Healthcare Sector Average

Performance Comparison

0%100%200%SE:ONCOSE:ATORXSE:BINVSE:IMMUSE:CANTASE:SPRINTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:ONCO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:ONCOOncopeptides AB1.64-3.30-66.83%
SE:ATORXAlligator Bioscience AB0.01-0.15-93.83%
SE:BINVBioInvent International AB2.09-27.96-93.04%
SE:IMMUImmunicum AB3.50-1.49-29.79%
SE:CANTACantargia AB1.29-1.94-60.03%
SE:SPRINTSprint Bioscience AB3.682.24155.56%

Oncopeptides AB Corporate Events

EU approves Pepaxti label expansion for third-line multiple myeloma

Nov 9, 2026

The European Commission approved an expanded marketing authorization for Oncopeptides’ Pepaxti, allowing its use in adults with multiple myeloma after at least two prior therapies whose disease is refractory to lenalidomide and the latest treatment....

Oncopeptides Reports Strong Pepaxti Growth and Glioblastoma Breakthrough

Nov 5, 2026

Oncopeptides reported third-quarter Pepaxti sales of SEK 28.5 million, up 41% year over year, while operating loss narrowed to SEK 36.5 million and cash stood at SEK 116.8 million. Nine-month sales rose 62% to nearly SEK 85 million, and trailing twel...

European real-world data supports Pepaxti in advanced myeloma

Nov 4, 2026

Oncopeptides, a biotechnology company focused on difficult-to-treat cancers, said two independent European real-world studies of Pepaxti plus dexamethasone in relapsed, refractory multiple myeloma have been accepted for presentation at ASH 2026. The...

Oncopeptides Boosts Capital Base with Directed Share Issue to Institutional Investors

Oct 30, 2026

Oncopeptides AB has increased its number of shares and voting rights following the completion of a directed share issue of 50,000,000 ordinary shares to Swedish and international institutional investors. As of October 30, 2026, the company’s total sh...

Oncopeptides to present Q3 2026 results in investor webcast

Oct 29, 2026

Oncopeptides AB has scheduled the publication of its third-quarter 2026 report for November 5 at 08:00 CET, underscoring its effort to maintain transparency with the market. The Stockholm-based biotech, which is focused on therapies for hard-to-treat...

Oncopeptides Raises SEK 100 Million in Discounted Directed Share Issue to Fund Glioblastoma Push

Oct 13, 2026

Oncopeptides AB has completed a directed share issue of 50 million new ordinary shares to Swedish and international institutional investors, raising SEK 100 million at a 13.9 percent discount to the latest closing price. The move follows participatio...

Oncopeptides Seeks SEK 100m in Directed Share Issue to Accelerate Glioblastoma Program

Oct 13, 2026

Oncopeptides plans a directed share issue of about SEK 100 million to Swedish and international institutional investors, deviating from shareholders’ preferential rights under an existing mandate. The company’s largest shareholder, HealthCap VIII LP,...

Oncopeptides to Brief Investors After Positive Glioblastoma Study Data

Oct 9, 2026

Oncopeptides AB, a Stockholm-listed biotech specializing in targeted cancer therapies, has built its business around proprietary Peptide Drug Conjugate technology to deliver cytotoxic agents directly into tumor cells. Its lead oncology product is alr...

Oncopeptides Reports Breakthrough Blood-Brain Barrier Data in Glioblastoma Study

Oct 9, 2026

Oncopeptides AB is a Stockholm-based biotech company focused on developing treatments for difficult-to-treat cancers, leveraging its proprietary Peptide Drug Conjugate platform. The firm is listed on Nasdaq Stockholm and is expanding in neuro-oncolog...

Oncopeptides earns EANO poster nod as PDC platform pushes into glioblastoma

Sep 22, 2026

Oncopeptides has secured acceptance of three abstracts on its next-generation alkylating peptide-drug conjugates in glioblastoma for presentation at the 2026 European Association of Neuro-Oncology Congress in Rome, marking its first major scientific...

Oncopeptides to Present New Pepaxti Data at Key Myeloma Meeting

Sep 21, 2026

Oncopeptides AB, a Stockholm-listed biotech focused on hard-to-treat cancers, is using its proprietary peptide-based platforms to develop targeted oncology drugs, led by the multiple myeloma therapy Pepaxti. With commercial rollout underway in Europe...

Oncopeptides Wins EMA Backing to Move Pepaxti Into Third-Line Myeloma Use

Sep 17, 2026

Oncopeptides has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use to expand Pepaxti’s label into third-line treatment for adult multiple myeloma patients refractory to lenalidomide and their last therapy. The...

Oncopeptides lifts Q2 sales 62% and moves to double Pepaxti market in Europe

Aug 27, 2026

Oncopeptides reported strong commercial momentum in the second quarter of 2026, with net sales rising 62 percent year-on-year to SEK 31.1 million and first-half sales up 74 percent to SEK 56.5 million. Despite an operating loss, the company ended the...

Oncopeptides to Present Q2 2026 Results as Oncology Commercialization Expands

Aug 20, 2026

Oncopeptides AB, a Stockholm‑listed biotech focused on targeted cancer therapies, is expanding commercialization of its flagship oncology drug across Europe and select international markets. With proprietary platforms and a lean footprint of around 7...

Oncopeptides Secures Slovenian List Price for Pepaxti in First CEE Expansion Step

Aug 17, 2026

Oncopeptides has secured a maximum allowed list price for its multiple myeloma drug Pepaxti in Slovenia, a key reference pricing market in Central and Eastern Europe, establishing a regulatory basis for subsequent market access and reimbursement talk...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026